JPH08504824A - 敗血症の予防および治療 - Google Patents

敗血症の予防および治療

Info

Publication number
JPH08504824A
JPH08504824A JP6515349A JP51534994A JPH08504824A JP H08504824 A JPH08504824 A JP H08504824A JP 6515349 A JP6515349 A JP 6515349A JP 51534994 A JP51534994 A JP 51534994A JP H08504824 A JPH08504824 A JP H08504824A
Authority
JP
Japan
Prior art keywords
conjugate
igg
antibiotic
pmb
binding
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP6515349A
Other languages
English (en)
Japanese (ja)
Inventor
ビー． キャロル，シーン
アール． フィルカ，ジョセフ
エス．ジー． ピュー，チャールズ
ヴィカス パッドハイ，ニシャ
Original Assignee
オフィディアン ファーマシューティカルズ，インコーポレーテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/169,701 external-priority patent/US5545721A/en
Application filed by オフィディアン ファーマシューティカルズ，インコーポレーテッド filed Critical オフィディアン ファーマシューティカルズ，インコーポレーテッド
Publication of JPH08504824A publication Critical patent/JPH08504824A/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/50—Cyclic peptides containing at least one abnormal peptide link
    • C07K7/54—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring
    • C07K7/60—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring the cyclisation occurring through the 4-amino group of 2,4-diamino-butanoic acid
    • C07K7/62—Polymyxins; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6807—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug or compound being a sugar, nucleoside, nucleotide, nucleic acid, e.g. RNA antisense
    • A61K47/6809—Antibiotics, e.g. antitumor antibiotics anthracyclins, adriamycin, doxorubicin or daunomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • C07K14/43509—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from crustaceans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/50—Cyclic peptides containing at least one abnormal peptide link
    • C07K7/54—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring
    • C07K7/56—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring the cyclisation not occurring through 2,4-diamino-butanoic acid
    • C07K7/58—Bacitracins; Related peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K9/00—Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof
    • C07K9/006—Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof the peptide sequence being part of a ring structure
    • C07K9/008—Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof the peptide sequence being part of a ring structure directly attached to a hetero atom of the saccharide radical, e.g. actaplanin, avoparcin, ristomycin, vancomycin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/531—Production of immunochemical test materials
    • G01N33/532—Production of labelled immunochemicals
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56911—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Communicable Diseases (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Insects & Arthropods (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
JP6515349A 1992-12-21 1993-12-20 敗血症の予防および治療 Pending JPH08504824A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US99538892A 1992-12-21 1992-12-21
US07/995,388 1992-12-21
US16406793A 1993-12-08 1993-12-08
US08/164,067 1993-12-08
US08/169,701 US5545721A (en) 1992-12-21 1993-12-17 Conjugates for the prevention and treatment of sepsis
US08/169,701 1993-12-17
PCT/US1993/012381 WO1994014437A1 (en) 1992-12-21 1993-12-20 Prevention and treatment of sepsis

Publications (1)

Publication Number Publication Date
JPH08504824A true JPH08504824A (ja) 1996-05-28

Family

ID=27388964

Family Applications (1)

Application Number Title Priority Date Filing Date
JP6515349A Pending JPH08504824A (ja) 1992-12-21 1993-12-20 敗血症の予防および治療

Country Status (5)

Country Link
EP (1) EP0679083A4 (de)
JP (1) JPH08504824A (de)
AU (1) AU693433B2 (de)
CA (1) CA2151386A1 (de)
WO (1) WO1994014437A1 (de)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009513572A (ja) * 2005-09-28 2009-04-02 ベントリア バイオサイエンス 腸管障害及び／又は下痢用の経口組成物

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6579696B1 (en) * 1992-12-21 2003-06-17 Promega Corporation Polymyxin B conjugates
US6086875A (en) * 1995-01-17 2000-07-11 The Brigham And Women's Hospital, Inc. Receptor specific transepithelial transport of immunogens
US6485726B1 (en) 1995-01-17 2002-11-26 The Brigham And Women's Hospital, Inc. Receptor specific transepithelial transport of therapeutics
US6030613A (en) * 1995-01-17 2000-02-29 The Brigham And Women's Hospital, Inc. Receptor specific transepithelial transport of therapeutics
AU2022380383A1 (en) * 2021-11-05 2024-06-13 David FLOSSDORF Method for detecting pathogenic gram-negative microorganisms and uses thereof

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4067776A (en) * 1975-11-25 1978-01-10 Research Foundation Of Children's Hospital Method for differential diagnosis of meningitis with a limulus lysate test
US4867973A (en) * 1984-08-31 1989-09-19 Cytogen Corporation Antibody-therapeutic agent conjugates
CA1203164A (en) * 1982-03-09 1986-04-15 Thomas J. Mckearn Antibody conjugates
JPS59186924A (ja) * 1983-04-08 1984-10-23 Kureha Chem Ind Co Ltd ヒト免疫グロブリン結合抗腫瘍剤
US4666884A (en) * 1984-04-10 1987-05-19 New England Deaconess Hospital Method of inhibiting binding of von Willebrand factor to human platelets and inducing interaction of platelets with vessel walls
US4918163A (en) * 1985-09-27 1990-04-17 Pfizer Inc. Monoclonal antibodies specific for lipid-A determinants of gram negative bacteria
WO1989004672A1 (en) * 1987-11-20 1989-06-01 The Upjohn Company Derivatives of lincosaminide antibiotics
DE68924783T2 (de) * 1988-09-30 1996-03-28 Neorx Corp Wässrige additivsysteme, verfahren und polymerteilchen.
ES2063326T3 (es) * 1989-11-15 1995-01-01 Sandoz Ltd Conjugados de polimixina.
WO1992020715A1 (en) * 1991-05-16 1992-11-26 Associates Of Cape Cod, Inc. Endotoxin binding and neutralizing protein and uses thereof
WO1995005393A2 (en) * 1993-08-18 1995-02-23 Morphosys Gesellschaft Für Proteinoptimierung Mbh Lipopolysaccharide-binding and neutralizing peptides

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009513572A (ja) * 2005-09-28 2009-04-02 ベントリア バイオサイエンス 腸管障害及び／又は下痢用の経口組成物
JP2013139477A (ja) * 2005-09-28 2013-07-18 Ventria Bioscience 経口投与される剤

Also Published As

Publication number Publication date
WO1994014437A1 (en) 1994-07-07
AU6226994A (en) 1994-07-19
EP0679083A1 (de) 1995-11-02
CA2151386A1 (en) 1994-07-07
AU693433B2 (en) 1998-07-02
EP0679083A4 (de) 1999-03-24

Similar Documents

Publication Publication Date Title
US5545721A (en) Conjugates for the prevention and treatment of sepsis
US6579696B1 (en) Polymyxin B conjugates
Gough et al. Antiendotoxin activity of cationic peptide antimicrobial agents
Zoja et al. Verotoxin glycolipid receptors determine the localization of microangiopathic process in rabbits given verotoxin-1
JP2009227680A (ja) 腸球菌抗原およびワクチン
US6660267B1 (en) Prevention and treatment of sepsis
US10870710B2 (en) Synthetic oligosaccharide subunits of the Psl exopolysaccharide of pseudomonas aeruginosa and uses thereof
US6632432B1 (en) Directed human immune globulin for the prevention and treatment of staphylococcal infections
US20130280300A1 (en) Polypeptides and Immunizing Compositions Containing Gram Positive Polypeptides and Methods of Use
EA006602B1 (ru) Применение стафилококковых и энтерококковых вакцин для защиты иммунокомпромиссного субъекта от бактериальных инфекций
AU2016312422A1 (en) Methods and compositions for immune protection against extra-intestinal pathogenic E. coli
JP2002539272A (ja) ブドウ球菌抗原及びワクチン
JPH07501545A (ja) 非連鎖球菌系細菌感染症の治療方法
CA1242982A (fr) Derives immunostimulants et leur procede de preparation
Paulovičová et al. The evaluation of β‐(1→ 3)‐nonaglucoside as an anti‐Candida albicans immune response inducer
JPH08504824A (ja) 敗血症の予防および治療
AU673508B2 (en) Directed human immune globulin for the prevention and treatment of staphylococcal infections
Colino et al. Noncovalent association of protein and capsular polysaccharide on bacteria-sized latex beads as a model for polysaccharide-specific humoral immunity to intact gram-positive extracellular bacteria
US5998381A (en) Compounds that bind bacterial pili
KR20110124060A (ko) Ｗｔａ를 유효성분으로 함유하는 백신 조성물
Warren et al. Protective Efficacy of CAP18106–138–Immunoglobulin G in Sepsis
JPH05505592A (ja) セプシスの治療用製剤製品
JP4160633B2 (ja) 共通のブドウ球菌抗原と広範に反応するオプソニン作用性抗体
JP5386361B2 (ja) エンテロコッカス・フェカリス菌抗原および／またはエンテロコッカス・フェシウム菌抗原
CA2513024A1 (en) Vibrio cholerae lps detoxified derivatives and immunogenic compositions containing them